

Supplement to: Quality of Life Associated with Ramucirumab Treatment in Patients with Advanced Gastric Cancer in Japan: Exploratory Analysis from the Phase III RAINBOW Trial

Journal: Clinical Drug Investigation

Authors: Kensei Yamaguchi, Yasuhiro Shimada, Shuichi Hironaka, Naotoshi Sugimoto, Yoshito Komatsu, Tomohiro Nishina, Yasushi Omuro, Takao Tamura, Yongzhe Piao, Gosuke Homma, Min-Hua Jen, Astra M. Liepa, Kei Muro*

***Corresponding author:** Kei Muro, MD; Department of Clinical Oncology, Aichi Cancer Center Hospital, 1-1 Kanokoden, Chikusa-ku, Nagoya, Japan; Email: kmuro@aichi-cc.jp

Supplementary Table 1 EORTC QLQ-C30 compliance by scheduled assessment^a

Time point (weeks)	Ramucirumab plus paclitaxel N=68			Placebo plus paclitaxel N=72		
	Number of patients expected to complete QLQ-C30	Number of patients completed QLQ-C30	Compliance (%)	Number of patients expected to complete QLQ-C30	Number of patients completed QLQ-C30	Compliance (%)
0 (Baseline)	68	68	100	72	72	100
6	64	56	87.5	60	57	95.0
12	53	39	73.6	29	21	72.4
18	39	27	69.2	17	10	58.8
24	26	16	61.5	14	7	50.0
30	16	11	68.8	9	5	55.6
36	15	7	46.7	5	2	40.0

^aCompliance at each assessment time point was defined as the number of patients who completed the QLQ-C30 divided by the number of patients at that time point. The expected number of patients at any post-baseline visit was equal to the number of patients who were alive and without disease progression

QLQ-C30 Quality-of-Life Questionnaire-Core 30